ALISO VIEJO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that CEO Ron Andrews is scheduled to participate in the OneMedPlace Emerging Healthcare Technologies Finance Forum. Andrews will make a presentation at 1:50 p.m. PST on Monday, January 7 and participate in a panel discussion on Personalized Medicine at 3:00 p.m. PST on Tuesday, January 8. The forum will be held January 7-8 at the Sir Francis Drake Hotel in Union Square in San Francisco.
A webcast of the presentation will be available on Friday, January 11, 2008 at http://www.onemedplace.com.
Clarient combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies.
The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics, Inc. partner company. For more information, visit http://www.clarientinc.com.
Safeguard Scientifics, Inc. (NYSE: SFE), a holding company, builds
value in growth-stage technology and life sciences businesses. Safeguard
provides growth capital as well as a range of strategic, operating and
management resources to our partner companies. Safeguard participates in
growth buyout financings, including corporate spin-outs and management
buyouts, expansion financings, industry consolidations and early-stage
Allen & Caron, Inc.
|SOURCE Clarient, Inc.|
Copyright©2008 PR Newswire.
All rights reserved